New strategies against Stenotrophomonas maltophilia: A serious worldwide intrinsically drug-resistant opportunistic pathogen

Expert Review of Anti-Infective Therapy

Volumn 12, Issue 1, 2014, Pages 1-4

  Brooke, Joanna S ^a  

^a DEPAUL UNIVERSITY   (United States)

Author keywords

cystic fibrosis; levofloxacin; multidrug resistant; respiratory pathogen; Stenotrophomonas maltophilia; ticarcillin clavulanate; tigecycline; trimethroprimsulfamethoxazole

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AZITHROMYCIN; AZTREONAM; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; COLISTIN; COTRIMOXAZOLE; LEVOFLOXACIN; MACROLIDE; POLYMYXIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE DERIVATIVE; TIGECYCLINE; TIMENTIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL TRANSMISSION; CYSTIC FIBROSIS; DRUG BLOOD LEVEL; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SPUTUM LEVEL; DRUG TOLERABILITY; HUMAN; HYPOGLYCEMIA; IMMUNOCOMPROMISED PATIENT; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; RESPIRATORY TRACT INFECTION; REVIEW; STENOTROPHOMONAS MALTOPHILIA; UNSPECIFIED SIDE EFFECT;

ANTI-INFECTIVE AGENTS; DRUG RESISTANCE, BACTERIAL; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; OPPORTUNISTIC INFECTIONS; STENOTROPHOMONAS MALTOPHILIA;

EID: 84893044756     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.2014.864553     Document Type: Review

References (30)

1. Looney WJ, Narita M, Muhlemann K. Stenotrophomonas maltophilia: an emerging opportunist human pathogen. Lancet Infect. Dis. 9(5), 312-323 (2009).
2. Liu Y-M, Chen Y-S, Toh H-S et al. In vitro susceptibilities of non-Enterobacteriaceae isolates from patients with intra-abdominal infections in the Asia-Pacific region from to 2010: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART). Int. J. Antimicrob. Agents 40(S1), S11-S17 (2012).
3. Gales AC, Castanheira M, Jones RN, Sader HS. Antimicrobial resistance among Gram-negative bacilli isolated from Latin America: results from SENTRY Antimicrobial Surveillance Program (Latin America, 2008-2010). Diagn. Microbiol. Infect. Dis. 73(4), 354-360 (2012).
4. Falagas ME, Kastoris AC, Vouloumanou EK, Dimopoulos G. Community-acquired Stenotrophomonas maltophilia infections: a systematic review. Eur. J. Clin. Microbiol. Infect. Dis. 28(7), 719-730 (2009).
5. Brooke JS. Stenotrophomonas maltophilia: an emerging global opportunistic pathogen. Clin. Microbiol. Rev. 25(1), 2-41 (2012).
6. Pompilio A, Crocetta V, Confalone P et al. Adhesion to and biofilm formation on IB3-1 bronchial cells by Stenotrophomonas maltophilia isolates from cystic fibrosis patients. BMC Microbiol. 10, 102 (2010).
7. Brooke JS, Vo A, Watts P, Davis NA. Mutation of a lipopolysaccharide synthesis gene results in increased biofilm of Stenotrophomonas maltophilia on plastic and glass surfaces. Ann. Microbiol. 58(1), 35-40 (2008).
8. Waters VJ, Gomez MI, Soong G, Amin S, Ernst R, Prince A. Immunostimulatory properties of the emerging pathogen Stenotrophomonas maltophilia. Infect. Immun. 75(4),1698-1703 (2007).
9. Di Bonaventura G, Pompilio A, Zappacosta R et al. Role of excessive inflammatory response to Stenotrophomonas maltophilia lung infection in DBA/2 mice and implications for cystic fibrosis. Infect. Immun. 78(6), 2466-2476 (2010).
10. Waters V, Yau Y, Prasad S et al. Stenotrophomonas maltophilia in cystic fibrosis. Serologic response and effect on lung disease. Am. J. Resp. Crit. Care Med. 183, 635-640 (2011).
11. Sanchez MB, Herna'ndez A, Mart́nez JL. Stenotrophomonas maltophilia drug resistance. Future Microbiol. 4(6), 655-660 (2009).
12. Abbott IJ, Slavin MA, Thursky KA, Turnidge JD, Worth LJ. Stenotrophomonas maltophilia: emerging disease patterns and challenges for treatment. Expert Rev. Anti Infect. Ther. 9(4), 471-488 (2011).
13. Berg G, Eberl L, Hartmann A. The rhizosphere as a reservoir for opportunistic human pathogenic bacteria. Environ. Microbiol. 7(11), 1673-1685 (2005).
14. Mart́nez JL. Antibiotics and antibiotic resistance genes in natural environments. Science 321(5887), 365-367 (2008).
15. Gulmez D, Ç akar A, ̧ Sener B, Karakaya J, Hasçelik G. Comparison of different antimicrobial susceptibility testing methods for Stenotrophomonas maltophilia and results of synergy testing. J. Infect. Chemother. 16(5), 322-328 (2010).
16. Milne KEN, Gould IM. Combination antimicrobial susceptibility testing of multidrug-resistant Stenotrophomonas maltophilia from cystic fibrosis patients. Antimicrob. Agents Chemother. 56(8), 4071-4077 (2012).
17. Goldberg E, Bishara J. Contemporary unconventional clinical use of co-trimoxazole. Clin. Microbiol. Infect. 18(1), 8-17 (2012).
18. Parkins MD, Elborn JS. Newer antibacterial agents and their potential role in cystic fibrosis pulmonary exacerbation management. J. Antimicrob. Chemother. 65(9), 1853-1861 (2010).
19. Farrell DJ, Sader HS, Jones RN. Antimicrobial susceptibilities of a worldwide collection of Stenotrophomonas maltophilia isolates tested against tigecycline and agents commonly used for S. maltophilia infections. Antimicrob. Agents Chemother. 54(6), 2735-2737 (2010).
20. Geller DE, Flume PA, Griffith DC et al. Pharmacokinetics and safety of MP-376 (Levofloxacin inhalation solution) in cystic fibrosis subjects. Antimicrob. Agents Chemother. 55(6), 2636-2640 (2011).
21. Wu K, Yau YCW, Matukas L, Waters V. Biofilm compared to conventional antimicrobial susceptibility of Stenotrophomonas maltophilia isolates from cystic fibrosis patients. Antimicrob. Agents Chemother. 57(3), 1546-1548 (2013).
22. Parra-Riffo H, Lemus-Penaloza J. Severe levofloxacin-induced hypoglycemia: a case report and literature review. Nefrologia 32(4), 546-547(2012).
23. Gould VC, Okazaki A, Avison MB. Coordinate hyperproduction of SmeZ and SmeJK efflux pumps extends drug resistance in Stenotrophomonas maltophilia. Antimicrob. Agents Chemother. 57(1), 655-657 (2013).
24. Ryan RP, Fouhy Y, Fernandez Garcia B et al. Interspecies signalling via the Stenotrophomonas maltophilia diffusible signal factor influences biofilm formation and polymyxin tolerance in Pseudomonas aeruginosa. Mol. Microbiol. 68(1), 75-86 (2008).
25. Fournier P-E, Drancourt M, Colson P, Rolain J-M, La Scola B, Raoult D. Modern clinical microbiology: new challenges and solutions. Nature Rev. Microbiol. 11(8), 574-585 (2013).
26. Ji Y, Lei T. Antisense RNA regulation and application in the development of novel antibiotics to combat multidrug resistant bacteria. Science Prog. 96(1), 43-602013).
27. Chan BK, Abedon ST, Loc-Carrillo C. Phage cocktails and the future of phage therapy. Future Microbiol. 8(6), 769-783 (2013).
28. LiPuma JJ, Rathinavelu S, Foster BK et al. In vitro activities of a novel nanoemulsion against Burkholderia and other multidrug-resistant cystic fibrosis-associated bacterial species. Antimicrob. Agents Chemother. 53(1), 249-255 (2009).
29. Pieren M, Tigges M. Adjuvant strategies for potentiation of antibiotics to overcome antimicrobial resistance. Curr. Opin. Pharmacol. 12(5), 551-555 (2012).
30. WHO. Public health importance of antimicrobial resistance. www.who.int/drugresistance/AMR-Importance/en/